FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine, namely to gynecology, and can be used for syndrome of ovary hyperstimulation, as well as for its prevention in a subject who is under treatment against infertility with gonadotropic hormone. For this purpose composition, which contains quinagolide in pharmaceutically acceptable carrier, is introduced to patient.
EFFECT: introduction of quinagolide, in contrast to other dophamine agonists, ensures high therapeutic efficiency in considerably smaller doses and is quickly excreted from organism, which reduces risk of toxicity for mother and fetus.
16 cl, 3 tbl, 6 ex, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| MEDICATION FOR TREATING ENDOMETRIOSIS | 2008 |
|
RU2423146C2 |
| VETERINARY ANTI-PROLACTIN COMPOSITION FOR RUMINANTS | 2009 |
|
RU2528892C2 |
| METHODS OF TREATING INFERTILITY | 2016 |
|
RU2723098C2 |
| COMPOSITION FOR TREATING INFERTILITY | 2016 |
|
RU2704252C2 |
| UNITARY COMBINATION OF FSH AND hCG | 2004 |
|
RU2332228C2 |
| METHOD FOR TREATING STERILITY | 2000 |
|
RU2226395C2 |
| USE OF CABERGOLINE IN TREATING PATHOLOGICAL CONDITIONS CAUSED BY HIGH LEVELS OF THE VASCULAR ENDOTHELIAL GROWTH FACTOR | 2016 |
|
RU2698728C1 |
| METHOD OF TREATING PATIENTS WITH SEVERE OVARY HYPERSTIMULATION SYNDROME | 2015 |
|
RU2603319C1 |
| METHOD OF TREATING EXTERNAL GENITAL ENDOMETRIOSIS | 2019 |
|
RU2732251C1 |
| METHOD FOR OVARIAN HYPERSTEMULATION SYNDROME PREDICTION IN IVF PROGRAM BASED ON VEGFA AND TSHR GENES POLYMORPHISMS DETERMINATION | 2016 |
|
RU2621634C1 |
